MY201184A - A sustained release hydrogel composition - Google Patents

A sustained release hydrogel composition

Info

Publication number
MY201184A
MY201184A MYPI2019005059A MYPI2019005059A MY201184A MY 201184 A MY201184 A MY 201184A MY PI2019005059 A MYPI2019005059 A MY PI2019005059A MY PI2019005059 A MYPI2019005059 A MY PI2019005059A MY 201184 A MY201184 A MY 201184A
Authority
MY
Malaysia
Prior art keywords
sustained release
hydrogel composition
release hydrogel
tocotrienol
niosome
Prior art date
Application number
MYPI2019005059A
Inventor
Ju Yen Fu
Tan Meam Yee Doryn
Lay Hong Chuah
Original Assignee
Malaysian Palm Oil Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malaysian Palm Oil Board filed Critical Malaysian Palm Oil Board
Priority to MYPI2019005059A priority Critical patent/MY201184A/en
Priority to KR1020227011201A priority patent/KR20220075345A/en
Priority to PCT/MY2020/050080 priority patent/WO2021045607A1/en
Publication of MY201184A publication Critical patent/MY201184A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a thermo-responsive hydrogel composition for sustained release of tocotrienol comprising chitosan; gelatin; calcium chloride; �-glycerophosphate; and niosome-encapsulated tocotrienol.
MYPI2019005059A 2019-09-03 2019-09-03 A sustained release hydrogel composition MY201184A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MYPI2019005059A MY201184A (en) 2019-09-03 2019-09-03 A sustained release hydrogel composition
KR1020227011201A KR20220075345A (en) 2019-09-03 2020-09-03 Sustained release hydrogel composition
PCT/MY2020/050080 WO2021045607A1 (en) 2019-09-03 2020-09-03 A sustained release hydrogel composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2019005059A MY201184A (en) 2019-09-03 2019-09-03 A sustained release hydrogel composition

Publications (1)

Publication Number Publication Date
MY201184A true MY201184A (en) 2024-02-08

Family

ID=74853375

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019005059A MY201184A (en) 2019-09-03 2019-09-03 A sustained release hydrogel composition

Country Status (3)

Country Link
KR (1) KR20220075345A (en)
MY (1) MY201184A (en)
WO (1) WO2021045607A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
CN105154481A (en) * 2006-08-01 2015-12-16 帝斯曼营养品股份公司 Oil producing microbes and methods of modification thereof
US9522114B1 (en) * 2014-03-27 2016-12-20 University Of South Florida Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin
KR102560269B1 (en) * 2017-03-24 2023-07-28 조이더마 아게 pharmaceutical composition

Also Published As

Publication number Publication date
WO2021045607A1 (en) 2021-03-11
KR20220075345A (en) 2022-06-08

Similar Documents

Publication Publication Date Title
WO2018136202A3 (en) Compounds and methods for cdk8 modulation and indications therefor
TWD191162S (en) Necklace
EP4316302A3 (en) Laceless shoe
PH12018500047B1 (en) Notch pathway signaling inhibitor compounds
MX2022011695A (en) Compounds for optically active devices.
MX2019009606A (en) Bis-compounds for optically active devices.
EP3695295B8 (en) Adaptive control of a wearable robot such as an orthesis or a prosthesis
PH12019502469A1 (en) Novel fragrance compositions and products with mood enhancing effects
MX2017015743A (en) Ror gamma (rory) modulators.
NZ732699A (en) Calcium carbonate for plant protection
MX2022001764A (en) Compositions comprising tigolaner for controlling parasites.
MX2018014278A (en) Microparticles comprising a sulphur-containing compound.
NZ728623A (en) Novel sulfonylaminobenzamide compounds as anthelmintics
PH12016502386B1 (en) Oral care compositions
MX2016016613A (en) Composition in the form of compacted particles and use thereof.
MX2019000986A (en) Protein-fortified food product.
MY201184A (en) A sustained release hydrogel composition
MX2020004662A (en) Targeted adjusting of the contour using corresponding specifications.
EA201992196A1 (en) METHOD FOR SYNTHESIS OF ZEOLITE CRYSTALS WITH AN EXTENDING AGENT
MX2019008338A (en) Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye.
MX2019008375A (en) Thiobenzoimidazole as fungicides.
EP4218748A3 (en) Bmp-mimetics
MY176732A (en) Additive composition for ground improvement
EA201800565A1 (en) COMPOSITION FOR THE TREATMENT OF EYE DISEASES CONTAINING (+) - AZASETRON
MX2021009261A (en) Fluorovinylbenzamide compound as pd-l1 immunomodulator.